Cardiovascular prevention in clinical practice (ESC and German Guidelines 2007)

Herz

Volumn 34, Issue 1, 2009, Pages 4-14

  Gohlke, Helmut ^a   Albus, Christian ^b   Gysan, Detlef Bernd ^c   Hahmann, Harry W ^d   Mathes, Peter ^e  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Ambulantes Kardiologisches R   (Germany)

^d Waldburg Zeil Kliniken Klinik Schwabenland   (Germany)

^e Kardiologische Abteilung   (Germany)

Author keywords

Cardiovascular disease; Number needed to treat; Obesity; Physical activity; Prevention; Risk stratification; Smoking

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALCOHOL CONSUMPTION; ARTERY DISEASE; BARE METAL STENT; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EXERCISE; GERMANY; GLUCOSE METABOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; MORTALITY; NUTRITION; OBESITY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SMOKING CESSATION; STABLE ANGINA PECTORIS; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; ARTICLE; CARDIOLOGY; PREVENTIVE MEDICINE; STANDARD;

CARDIOLOGY; CARDIOVASCULAR DISEASES; GERMANY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE MEDICINE;

EID: 63049127730     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-009-3196-7     Document Type: Review

References (96)

1. U. Keil A.P. Fitzgerald H,. Gohlke 2005 Risk of death from heart-circulatory diseases. The new SCORE - Germany - tables for primary prevention Dtsch Ärztebl 102 A1808 12
2. J. Stamler R. Stamler J.D. Neaton 1999 Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women JAMA 282 2012 8
3. E.S. Ford U.A. Ajani J.B. Croft 2007 Explaining the decrease in U.S. deaths from coronary disease, 1980-2000 N Engl J Med 356 2388 98
4. S.L. Hardoon P.H. Whincup L.T. Lennon 2008 How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study Circulation 117 598 604
5. Diabetes Prevention Program Research Group. 2003 Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Diabetes Care 26 2518 23
6. J.P. Greving E. Buskens H. Koffijberg 2008 Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Circulation 117 2875 83
7. H. Löwel C. Melsinger M. Heier 2002 Sex specific trends of sudden cardiac death and acute myocardial infarction: results of the population-based KORA/MONICA-Augsburg Register 1985 to 1998 Dtsch Med Wochenschr 127 2311 6
8. S.C. Smith J. Allen S.N. Blair 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2363 72
9. I. Graham D. Atar K. Borch-Johnsen 2007 European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 Suppl2 S1 113
10. Gohlke H, Albus C, Bönner G, et al. Pocket-Leitlinien: risikoadjustierte Prävention von Herz und Kreislauferkrankungen ( http://www.leitlinien.dgk.org ; Pocket Leitlinien, accessed November 1, 2008).
11. K.W. Lauterbach A. Gerber G. Klever-Deichert 2005 Cost effectiveness of prevention of coronary disease in Germany Z Kardiol 94 Suppl3 :III/100 4
12. H.M. Colhoun D.J. Betteridge P.N. Durrington CARDS Investigators 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 96
13. P.G. Steg D.L. Bhatt P.W.F. Wilson REACH Registry Investigators 2007 One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 1197 206
14. G. Assmann P. Cullen H. Schulte 2002 Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the PROspective CArdiovascular Münster (PROCAM) study Circulation 105 310 5
15. H. Gohlke M. Winter M. Karoff 2007 CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention Eur J Cardiovasc Prev Rehabil 14 141 8
16. M. Ezzati S. Van der Hoorn A. Rodgers Comparative Risk Assessment Collaborating Group 2003 Estimates of global and regional potential health gains from reducing multiple major risk factors Lancet 362 271 80
17. H. Gohlke 2004 Prävention durch Lebensstiländerung: Was ist gesichert? Herz 29 139 44
18. C.E. Bartecchi T.D. MacKenzie R.W. Schrier 1994 The human costs of tobacco use (first of two parts) N Engl J Med 330 907 12
19. S. Yusuf S. Hawken S. Ounpuu 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 52
20. J.A. Ambrose R.S. Barua 2004 The pathophysiology of cigarette smoking and cardiovascular disease. An update J Am Coll Cardiol 43 1731 7
21. C. Meisinger J. Baumert N. Khuseyinova 2005 Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population Circulation 112 651 7
22. H. Löwel C. Meisinger M. Heier 2005 The population-based acute myocardial infarction (AMI) registry of the MONICA/KORA study region of Augsburg Gesundheitswesen 67 31 7
23. H. Gohlke S. Yusuf 2007 Quantitating loss of life by smoking a single cigarette Clin Res Cardiol 96 522 3
24. N.R. Anthonisen M.A. Skeans R.A. Wise Lung Health Study Research Group 2005 The effects of a smoking cessation intervention on 14.5-year mortality a randomized clinical trial Ann Intern Med 142 233 9
25. R.T. Van Domburg W. Scholte op Reimer S.E. Hoeks 2008 Three life-years gained from smoking cessation after coronary artery bypass surgery: A 30-year follow-up study Am Heart J 156 473 6
26. T. Raupach K. Schäfer S. Konstantinides 2006 Passive smoking has immediate effects on the clotting system and endothelial function. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm Eur Heart J 27 386 92
27. S.N. Blair J.B. Kampert H.W. Kohl III 1996 Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women JAMA 276 205 10
28. D. König G. Bönner A. Berg 2007 Bedeutung von Adipositas und Bewegungsmangel in der kardiovaskulären Primärprävention Herz 32 553 9
29. T.A. Lakka J.M. Venäläinen R. Rauramaa 1994 Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men N Engl J Med 330 1549 54
30. J.A.E. Manson F.B. Hu J.W. Rich-Edwards 1999 A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women N Engl J Med 341 650 8
31. R.S. Paffenbarger R.T. Hyde A.L. Wing 1986 Physical activity, all cause mortality and longevity of college alumni N Engl J Med 314 605 13
32. L. Sandvik J. Erikssen E. Thaulow 1993 Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men N Engl J Med 328 533 7
33. F.B. Hu W.C. Willett T. Li 2004 Adiposity as compared with physical activity in predicting mortality among women N Engl J Med 351 2694 703
34. H.D. Sesso R.S. Paffenbarger I.-M. Lee 2000 Physical activity and coronary heart disease in men. The Harvard Alumni Health Study Circulation 102 975 80
35. I.-M. Lee H.D. Sesso Y. Oguma 2004 The "weekend warrior" and risk of mortality Am J Epidemiol 160 636 41
36. F.C.H. Bijnen C.J. Caspersen E.J.M. Feskens 1998 Physical activity and 10-year mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study Arch Intern Med 158 1499 505
37. A.A. Hakim J.D. Curb H. Petrovitch 1999 Effects of walking on coronary heart disease in elderly men - the Honolulu Heart Program Circulation 100 9 13
38. G. Schuler 2005 Körperliche Aktivität Z Kardiol 94 III/11 4
39. H.-G. Predel T. Schramm 2006 Körperliche Aktivität bei arterieller Hypertonie Herz 31 525 30
40. A. Linke S. Möbius-Winkler R. Hambrecht 2006 Körperliches Training in der Behandlung von KHK und Adipositas Herz 31 224 33
41. R. Hambrecht 2004 Sport als Therapie Herz 29 381 90
42. M. Hanefeld W. Metzler C. Köhler 2006 Das metabolische Syndrom:.,common soil" für Diabetes und Atherosklerose. Neue Möglichkeiten für eine integrierte Therapie Herz 31 246 54
43. National Institutes of Health. 1998 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report Obes Res 6 Suppl2 51S 209S
44. G. Giacchetti E. Faloia B. Mariniello 2002 Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects Am J Hypertens 15 381 8
45. J.P. Bastard C. Jardel E. Bruckert 2000 Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss J Clin Endocrinol Metab 85 3338 42
46. J.S. Yudkin C.D. Stehouwer J.J. Emeis 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19 972 8
47. J.F. Keaney M.G. Larson R.S. Vasan 2003 Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study Arterioscler Thromb Vasc Biol 23 434 9
48. D.R. Seals P.E. Gates 2005 Stiffening our resolve against adult weight gain [Editorial] Hypertension 45 175 7
49. N.F. Murphy K. MacIntyre S. Stewart 2006 Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley-Study) Eur Heart J 27 96 106
50. K.R. Fontaine D.T. Redden C. Wang 2003 Years of life lost due to obesity JAMA 289 187 93
51. H.C. McGill Jr C.A. McMahan E.E. Herderick 2002 Obesity accelerates the progression of coronary atherosclerosis in young men Circulation 105 2712 8
52. C.A. McMahan S.S. Gidding Z.A. Fayad Pathobiological Determinants of Atherosclerosis in Youth Research Group 2005 Risk scores predict atherosclerotic lesions in young people Arch Intern Med 165 883 90
53. S. Mora L.R. Yanek T.F. Moy 2005 Interaction of body mass index and Framingham Risk Score in predicting incident coronary disease in families Circulation 111 1871 6
54. A. Peeters J.J. Barendregt F. Willekens 2003 Obesity in adulthood and its consequences for life expectancy: a life-table analysis Ann Intern Med 138 24 32
55. E.E. Calle C. Rodriguez K. Walker-Thurmond 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 1625 38
56. E.E. Calle M.J. Thun J.M. Petrelli 1999 Body-mass index and mortality in a prospective cohort of U.S. adults N Engl J Med 341 1097 105
57. GISSI-Prevenzione Investigators. 1999 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 447 55
58. P.N. Mitrou V. Kipnis A.C.M. Thiébaut 2007 Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study Arch Intern Med 167 2461 8
59. L. Djoussé J.M. Gaziano 2007 Alcohol consumption and risk of heart failure in the Physicians' Health Study I Circulation 115 34 9
60. M.V. Singer S. Teyssen 2001 Serie Alkoholismus - alkoholassozi-ierte Organschäden Dtsch Ärztebl 98 A2109 20
61. Antithrombotic Trialists' Collaboration. 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Br Med J 324 71 86
62. S. Juul-Müller N. Edvardsson B. Jahnmatz Swedish Angina Pectoris Aspirin Trial 1992 Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris Lancet 340 1421 5
63. D.T. Mangano Multicenter Study of Perioperative Ischemia Research Group 2002 Aspirin and mortality from coronary bypass surgery N Engl J Med 347 1309 17
64. J.M. Gaspoz P.G. Coxson P.A. Goldman 2002 Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease N Engl J Med 346 1800 6
65. A. Nicolucci G. De Berardis M. Sacco 2007 AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions Eur Heart J 28 1925 7
66. J. Belch A. MacCuish I. Campbell Prevention of Progression of Arterial DiseaseDiabetes Study Group 2008 Diabetes Registry Group, and Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 a1840
67. European Society of Cardiology. Cardiovascular disease prevention in clinical practice: pocket guidelines. Sophia Antipolis: European Society of Cardiology, 2007 ( http://www.escardio.org/guidelines-surveys/products/pocket/ Pages/PREV.aspx ).
68. CAPRIE Steering Committee. 1996 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1329 39
69. C.W. Hamm H.-R. Arntz C. Bode 2004 Leitlinien. Akutes Koronarsyndrom (ACS) Teil 1: ACS ohne persistierende ST-Hebung Z Kardiol 93 72 90
70. Cholesterol Treatment Trialists' 2008 Efficacy of cholesterol-owering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 25
71. P.M. Ridker E. Danielson F.A.H. Fonseca 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 207
72. P. Deedwania P. Barter R. Carmena Treating to New Targets Investigators 2006 Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study Lancet 368 919 28
73. C.P. Cannon E. Braunwald C.H. McCabe Pravastatin or Atorvastatin EvaluationInfection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators 2004 Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495 504
74. K.K. Ray C.P. Cannon C.H. McCabe PROVE IT-TIMI 22 Investigators 2005 Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol 46 1405 10
75. S. Yusuf R. Peto J. Lewis 1985 Beta-blockade during and after myocardial infarction: an overview of randomized trials Prog Cardiovasc Dis 27 335 71
76. M. Packer A.J.S. Coats M.B. Fowler Carvedilol Prospective Randomized Cumulative Survival Study Group 2001 Effect of carvedilol on survival in severe chronic heart failure N Engl JMed 344 1651 8
77. R.J. Gibbons J. Abrams K. Chatterjee 2003 American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Committee on the Management of Patients with Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina) Circulation 107 149 58
78. S. Bangalore F.H. Messerli J.B. Kostis 2007 Cardiovascular protection using beta-blockers. A critical review of the evidence J Am Coll Cardiol 50 563 72
79. S. Bangalore S. Sawhney F.H. Messerli 2008 Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension J Am Coll Cardiol 52 1482 9
80. AIRE Study Investigators. 1993 Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Lancet 342 821 8
81. M.A. Pfeffer J.J.V. McMurray E.J. Velazquez Valsartan in Acute Myocardial Infarction Trial Investigators 2003 Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 1893 906
82. C. Torp-Pedersen L. Kober 1999 Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation Lancet 354 9 12
83. M.D. Flather S. Yusuf L. Køber ACE-Inhibitor Myocardial Infarction Collaborative Group 2000 Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 355 1575 81
84. The Heart Outcomes Prevention Evaluation Study Investigators. 2000 Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 145 53
85. The PEACE Trial Investigators. 2004 Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2058 68
86. D.G. Hackam D. Thiruchelvam D.A. Redelmeier 2006 Angiotensin-converting enzyme inhibitors and aortic rupture: a population- based case-control study Lancet 368 659 65
87. P. Jong C. Demers R.S. McKelvie 2002 Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials J Am Coll Cardiol 39 463 70
88. M.A. Pfeffer E. Braunwald L.A. Moye The SAVE Investigators 1992 Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial N Engl J Med 327 669 77
89. S. Yusuf H.-C. Diener R.L. Sacco 2008 Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 1225 37
90. The ALLHAT Collaborative Research Group. 2002 Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2981 97
91. J.A. Staessen J.G. Wang L. Thijs 2001 Cardiovascular prevention and blood pressure reduction: a meta-analysis Lancet 358 1305 15
92. B. Pitt W. Remme F. Zannad Eplerenone Post-Acute Myocardial Infarction Heart Failure EfficacySurvival Study Investigators 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 21
93. E.F. Lewis L.A. Moye J.L. Rouleau 2003 Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study J Am Coll Cardiol 42 1446 53
94. M. Anselmino H. Gohlke L. Mellbin 2008 Cardiovascular prevention in patients with diabetes and prediabetes Herz 33 170 7
95. M.M. Davis K. Taubert A.L. Benin 2006 Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology: this science advisory is consistent with the recommendations of the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices Circulation 114 1549 53
96. E.P. Gurfinkel R. Leon de la Fuente O. Mendiz 2004 Flu Vaccination in Acute Coronary Syndromes and Planned Percutaneous coronary Interventions (FLUVACS) study Eur Heart J 25 25 31